(258) argues that there are several points that were inadequately discussed, which may explain the outcome, including uncertainty of whether IDO1 activity was sufficiently inhibited within the tumor, pathways bypassing IDO1 were not considered and the choice of immunotherapy over DNA damaging therapy, highlighting the need for increased understanding of metabolism within the TME. Here, IDO1 is linked to neoplasm.